THE INDIAN PHARMACIST Official Circular Pharmacy LogoTHE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINAL PLANT & BOTANICAL REFERENCE PROFILE CODE: [BOT-05] ID: TIP-MED-000584

Brahmi (Bacopa monnieri)

Active Ingredient / Scientific Identity: Bacopa monnieri (L.) Wettst. • Class: Pharmacognosy & Phytochemistry โ€ข Plantaginaceae (formerly Scrophulariaceae) (Dried Whole Creeping Herb)

โš–๏ธ Compare Profile

1. Clinical & Scientific Overview

Brahmi (Bacopa monnieri) (TIP-MED-000584, Reference Code [BOT-05]) is classified under Medicinal Plants, Botanicals & Phytopharmaceuticals as a Pharmacognosy & Phytochemistry โ€ข Plantaginaceae (formerly Scrophulariaceae) (Dried Whole Creeping Herb). Within the Indian regulatory and compendial framework, it is governed under Indian Pharmacopoeia (IP) Herbal Monograph, API Part I Vol II, and FSSAI Standardized Botanical Extract..

Verified Indian Market Examples / Compendial Status:
Standardised Pharmacopoeial Crude Drug / Extract (IP / API Reference)
Botanical Standardisation Note: Authenticate by macroscopic, microscopic, and HPTLC/HPLC marker assay (Dammarane-type triterpenoid saponins โ€” Bacosides A and B (Bacoside A3, Bacopaside II, Jujubogenin isomer, Bacopasaponin C โ€” IP standardized to >=20%โ€“50% total bacosides)) per Indian Pharmacopoeia (IP) and Ayurvedic Pharmacopoeia of India (API).
Dosage Forms & Available Strengths:
Official Plant Part: Dried Whole Creeping Herb | Marker Compounds: Dammarane-type triterpenoid saponins โ€” Bacosides A and B (Bacoside A3, Bacopaside II, Jujubogenin isomer, Bacopasaponin C โ€” IP standardized to >=20%โ€“50% total bacosides)
Routes: Oral / Topical as specified by classical API or standardized extract monograph

Pharmacognosy, Phytochemistry & Botanical Standardisation

Accepted Botanical Binomial & Authority: Bacopa monnieri (L.) Wettst.

Botanical Family: Plantaginaceae (formerly Scrophulariaceae)

Official Authenticated Plant Part: Dried Whole Creeping Herb

Major Phytochemical Constituents & IP/API Marker Compounds: Dammarane-type triterpenoid saponins โ€” Bacosides A and B (Bacoside A3, Bacopaside II, Jujubogenin isomer, Bacopasaponin C โ€” IP standardized to >=20%โ€“50% total bacosides)

Brahmi (Bacopa monnieri) Botanical Reference Illustration

Traditional / Classical Ayurvedic Context: Classical Ayurvedic Medhya Rasayana (nootropic and memory-support botanical).

Modern Clinical Evidence Assessment (Clearly Distinguished from Traditional Use): Multiple 12-week double-blind RCTs demonstrate modest improvements in delayed verbal recall and cognitive processing speed at 300 mg/day of standardized extract (requires 8โ€“12 weeks of continuous intake; no acute stimulant effect).

Quality Control, Adulteration & Contaminant Limits: Authenticate via HPTLC/HPLC marker assay; screen for heavy metals (Lead <=10 ppm, Arsenic <=3 ppm, Cadmium <=0.3 ppm, Mercury <=1 ppm), microbial load, and aflatoxins B1/B2/G1/G2 per IP/API.

Indian Regulatory Classification (ASU vs Phytopharmaceutical vs FSSAI): Indian Pharmacopoeia (IP) Herbal Monograph, API Part I Vol II, and FSSAI Standardized Botanical Extract.

3. Mechanism of Action & Pharmacodynamics

Major Phytochemical Constituents & Pharmacological Actions: Dammarane-type triterpenoid saponins โ€” Bacosides A and B (Bacoside A3, Bacopaside II, Jujubogenin isomer, Bacopasaponin C โ€” IP standardized to >=20%โ€“50% total bacosides). Multiple 12-week double-blind RCTs demonstrate modest improvements in delayed verbal recall and cognitive processing speed at 300 mg/day of standardized extract (requires 8โ€“12 weeks of continuous intake; no acute stimulant effect).

4. Therapeutic Indications & Evidence-Supported Uses

  • Traditional / Classical Context: Classical Ayurvedic Medhya Rasayana (nootropic and memory-support botanical).
  • Modern Clinical Evidence Assessment: Multiple 12-week double-blind RCTs demonstrate modest improvements in delayed verbal recall and cognitive processing speed at 300 mg/day of standardized extract (requires 8โ€“12 weeks of continuous intake; no acute stimulant effect).

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Pharmacognostic & Clinical Evidence Summary: Multiple 12-week double-blind RCTs demonstrate modest improvements in delayed verbal recall and cognitive processing speed at 300 mg/day of standardized extract (requires 8โ€“12 weeks of continuous intake; no acute stimulant effect).

Administration & Meal Timing: Authenticated Plant Part Used: Dried Whole Creeping Herb. Cholinergic GI side effects (increased stool frequency, abdominal cramping, nausea โ€” take with meals); may potentiate acetylcholinesterase inhibitors (donepezil, rivastigmine) and cause mild bradycardia.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Complex multicomponent phytoconstituent disposition involving intestinal deglycosylation by gut microbiota, hepatic Phase II glucuronidation/sulfation, and potential modulation of CYP450 and P-gp efflux pumps.
Metabolism & Biotransformation:
Intestinal microbial hydrolysis and hepatic Phase I/II biotransformation of secondary metabolites.
Elimination & Renal Adjustment:
Avoid unstandardised herbal extracts in Stage 3โ€“5 Chronic Kidney Disease (risk of hyperkalaemia or nephrotoxic adulterants).
Hepatic Impairment Considerations:
Avoid high-dose concentrated botanical extracts in pre-existing hepatic disease; discontinue immediately if jaundice or transaminase elevation occurs.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Hypersensitivity to Bacopa monnieri (L.) Wettst. or other members of the Plantaginaceae (formerly Scrophulariaceae) family
  • Cholinergic GI side effects (increased stool frequency, abdominal cramping, nausea โ€” take with meals); may potentiate acetylcholinesterase inhibitors (donepezil, rivastigmine) and cause mild bradycardia.

Key Clinical Precautions: Cholinergic GI side effects (increased stool frequency, abdominal cramping, nausea โ€” take with meals); may potentiate acetylcholinesterase inhibitors (donepezil, rivastigmine) and cause mild bradycardia.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Cholinergic GI side effects (increased stool frequency, abdominal cramping, nausea โ€” take with meals); may potentiate acetylcholinesterase inhibitors (donepezil, rivastigmine) and cause mild bradycardia.
Serious / Dose-Limiting Adverse Effects:
  • Cholinergic GI side effects (increased stool frequency, abdominal cramping, nausea โ€” take with meals); may potentiate acetylcholinesterase inhibitors (donepezil, rivastigmine) and cause mild bradycardia.

9. Major Drugโ€“Drug, Drugโ€“Food & Drugโ€“Herb Interactions

  • Cholinergic GI side effects (increased stool frequency, abdominal cramping, nausea โ€” take with meals); may potentiate acetylcholinesterase inhibitors (donepezil, rivastigmine) and cause mild bradycardia.

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Verify botanical binomial authenticity (exclude adulterants/substitutes), HPTLC marker content, heavy metal limits (Pb, As, Cd, Hg), aflatoxins, and pesticide residues per IP/API standards.

Pharmacist Patient Counselling Points:

  • Natural or herbal origin does NOT automatically mean risk-free; always disclose botanical supplements to your doctor and pharmacist.
  • Cholinergic GI side effects (increased stool frequency, abdominal cramping, nausea โ€” take with meals); may potentiate acetylcholinesterase inhibitors (donepezil, rivastigmine) and cause mild bradycardia.
  • Never discontinue prescribed allopathic chronic disease medicines (antihypertensives, antidiabetics, anticonvulsants, or antivirals) in favour of unverified herbal products.

Storage, Stability & Dispensing Safeguards: Store dried botanical material and extracts in airtight, light-resistant containers below 25ยฐC protected from humidity and fungal/aflatoxin contamination.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4โ€“5 Portal First-Pass Metabolism 1. Oral Administration โ€ข Tablet / Capsule swallowed โ€ข Gastric emptying to duodenum pH 1.5โ€“3.5 (Stomach) 2. Disintegration & Dissolution โ€ข Tablet breaks into granules โ€ข API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption โ€ข Crosses intestinal villi โ€ข Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation โ€ข Mesenteric veins → Portal vein โ€ข Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism โ€ข Gut & hepatic CYP450 extraction โ€ข High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation โ€ข Hepatic vein → IVC → Heart โ€ข Unbound vs Albumin-bound drug Only FREE drug is active 7โ€“8. Tissue Distribution (Vd) โ€ข Capillary permeation to organs โ€ข Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action โ€ข Receptors (GPCR, Ion channel) โ€ข Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation โ€ข Phase I (CYP450 Oxidation/Hydrolysis) โ€ข Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination โ€ข Nephron: Filtration + Secretion โˆ’ Reabsorption โ€ข Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body โ€ข Urine (Primary polar metabolite route) โ€ข Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey โ€” 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP โ€” Herbs and Herbal Products Addendum); Ayurvedic Pharmacopoeia of India (API โ€” Ministry of AYUSH); CDSCO Rule 122E Phytopharmaceutical Drug Guidelines.

Official Verification Portals: Ministry of AYUSH โ€” Pharmacopoeia Commission for Indian Medicine & Homoeopathy (PCIM&H) • Indian Pharmacopoeia Commission (IPC) โ€” Herbal Monographs • CDSCO โ€” Drugs and Cosmetics Rules (ASU & Phytopharmaceuticals)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.